In Vitro & In Vivo Diagnostic Substances Industry - SEC Form 4 Insider Trading Screener

Manufacturing Sector - Chemicals - In Vitro & In Vivo Diagnostic Substances
General
Tickers
Insider
Sh Price $
Lqdty M$
Date
Filing Date
  
Trade Date
  
Filing Delay
N Days Ago
Transaction Filing
P - Purchase
S - Sale
A - Grant
D - Sale to Iss
G - Gift
F - Tax
M - Option Ex
X - Option Ex
C - Cnv Deriv
W - Inherited
No deriv Multiple Days
Traded K$
Own Chg %
Industry
Insider Title   Officer
    COB
    CEO
    Pres
    COO
    CFO
    GC
    VP
  Director
  10% Own
  Other
Group by
Sort by
Max Results
Page
clear
100 results - Yahoo - Google - Finviz - Stockcharts - Tradingview - Stocktwits - SEC
TCcnt1d1w1m6m
P28-0+9+15-6
S71-0-1-1+17

X

Filing Date

Trade Date

Ticker

Company

Insider Name

Insider Title

Trade Type 

Share Price

Shares Traded

Shares Owned

Own chg

Value Traded

1d ret

1w ret

1m ret

6m ret

D
2017-03-20
OXFDOxford Immunotec Global PlcKeiley Elizabeth MSVP, GCS - Sale+OE$16.05-3,00030,614-9%-$48,150
2017-03-17
LNTHLantheus Holdings, Inc.Avista Capital Partners Gp, LLC10%S - Sale$12.20-3,000,0003,442,208-47%-$36,600,0000
2017-03-17
LNTHLantheus Holdings, Inc.Venkataraman SriramDir, 10%S - Sale$12.20-3,000,0003,442,208-47%-$36,600,0000
2017-03-17
LNTHLantheus Holdings, Inc.Burgstahler David FDir, 10%S - Sale$12.20-3,000,0003,442,208-47%-$36,600,0000
2017-03-15
LNTHLantheus Holdings, Inc.Healey Timothy GSVP, CommercialS - Sale$12.42-11,31483,112-12%-$140,555-1
M
2017-03-13
ICCCImmucell Corp /de/Tomsche David ScottDirP - Purchase$5.43+2,00072,789+3%+$10,861+2+4
M
2017-03-09
NTLAIntellia Therapeutics, Inc.Atlas Venture Associates Ix, L.P.10%S - Sale$13.91-21,1323,729,788-1%-$293,843+1+2
M
2017-03-09
NTLAIntellia Therapeutics, Inc.Formela Jean FrancoisDirS - Sale$13.91-21,1323,729,788-1%-$293,843+1+2
2017-02-28
IDXXIdexx Laboratories Inc /deHenderson Rebecca MDirS - Sale$145.19-6,50014,950-30%-$943,7210+2
AD
2016-08-25
IDXXIdexx Laboratories Inc /deHenderson Rebecca MDirS - Sale+OE$110.44-9,92421,450-32%-$1,095,9530+2
D
2017-03-03
OXFDOxford Immunotec Global PlcEdwardson PeterChief Operations OfficerS - Sale+OE$14.92-5,92348,271-11%-$88,38200
2017-03-01
IDXXIdexx Laboratories Inc /deKingsley Lawrence DDirP - Purchase$146.48+1,0001,135+741%+$146,480+1+1
D
2017-02-27
ABIOArca Biopharma, Inc.Selby Brian L.VP, FinanceS - Sale+OE$2.56-1612,389-6%-$4120-6
D
2017-02-28
ABIOArca Biopharma, Inc.Ozeroff Christopher DavidS.VP, GCS - Sale+OE$2.61-46517,935-3%-$1,2140-6
D
2017-02-28
ABIOArca Biopharma, Inc.Keuer Thomas ACOOS - Sale+OE$2.61-46514,435-3%-$1,2140-6
D
2017-02-28
ABIOArca Biopharma, Inc.Bristow Michael RPres, Chief Exec OfficS - Sale+OE$2.61-76387,320-1%-$1,9910-6
DM
2017-02-24
QDELQuidel Corp /de/Bryant Douglas CPres, CEOS - Sale+OE$21.39-106,920280,306-28%-$2,287,314+5+5
D
2017-02-22
IDXXIdexx Laboratories Inc /deAyers Jonathan WCOB, Pres, CEOS - Sale+OE$142.57-35,0001,108,947-3%-$4,990,1350+3
M
2017-02-22
MYGNMyriad Genetics IncHenderson John TDirP - Purchase$18.66+6,00042,824+16%+$111,930+1+3
2017-02-16
IDXXIdexx Laboratories Inc /deEnd William TDirS - Sale$141.71-5,00050,256-9%-$708,5340+1+5
D
2017-02-17
VRMLVermillion, Inc.Feinberg Larry N* See Remarks, 10%P - Purchase$1.40+617,7319,825,289+7%+$864,823+18+21+23
D
2017-02-13
VRMLVermillion, Inc.Schuler Henri George10%P - Purchase$1.40+1,947,0528,109,840+32%+$2,725,873-6+22+27
D
2017-02-13
VRMLVermillion, Inc.Schuler Jack W10%P - Purchase$1.40+974,0819,805,249+11%+$1,363,713-6+22+27
D
2017-02-13
VRMLVermillion, Inc.Jordan Veronica GhDirP - Purchase$1.40+6,69570,315+11%+$9,373-6+22+27
D
2017-02-13
VRMLVermillion, Inc.Ferrara FredCOOP - Purchase$1.40+6,6956,695New+$9,373-6+22+27
D
2017-02-13
VRMLVermillion, Inc.Palmieri Valerie BarberPres, CEOP - Purchase$1.40+10,04258,542+21%+$14,059-6+22+27
D
2017-02-13
VRMLVermillion, Inc.Schoen EricSVP Finance, CAOP - Purchase$1.40+3,34729,872+13%+$4,686-6+22+27
D
2017-02-13
VRMLVermillion, Inc.Lafrance James TDirP - Purchase$1.40+6,695190,094+4%+$9,373-6+22+27
D
2017-02-13
VRMLVermillion, Inc.Burns James SDirP - Purchase$1.40+15,000265,922+6%+$21,000+11+33+38
D
2017-02-08
IDXXIdexx Laboratories Inc /deMcKeon Brian PEVP, CFOS - Sale+OE$141.63-9,92435,311-22%-$1,405,59100+6
D
2017-02-08
IDXXIdexx Laboratories Inc /deAyers Jonathan WCOB, Pres, CEOS - Sale+OE$141.63-36,2501,088,486-3%-$5,134,17100+6
D
2017-02-08
IDXXIdexx Laboratories Inc /deJunius Daniel MDirS - Sale+OE$141.75-3,0002,495-55%-$425,26400+6
D
2017-02-06
OXFDOxford Immunotec Global PlcWrighton-Smith PeterCEOS - Sale+OE$13.36-25,000438,495-5%-$333,875+1+1+12
2017-02-02
VIVOMeridian Bioscience IncLueke MelissaEVP, CFOP - Purchase$12.59+4,000167,071+2%+$50,356+5+5+7
2017-01-26
VIVOMeridian Bioscience IncBaldini LawrenceEVP, Pres Global OperationsP - Purchase$12.70+4,000106,934+4%+$50,800+2+1+2
D
2017-01-09
NEOGNeogen CorpParnell Jack CDirS - Sale+OE$66.04-6,00013,555-31%-$396,222-10-1
D
2017-01-09
NEOGNeogen CorpMorrical Terri AVPS - Sale+OE$66.12-27,60039,583-41%-$1,824,796-10-1
D
2017-01-04
NEOGNeogen CorpQuinlan Steven J.VP, CFOS - Sale+OE$66.13-5,35210,103-35%-$353,9470+10
2017-01-04
BIOPBioptix, Inc.Honig Barry C10%P - Purchase$4.22+4,000443,585+1%+$16,880-5-19-32
D
2016-12-23
NEOGNeogen CorpMorrical Terri AVPS - Sale+OE$65.79-21,60039,583-35%-$1,421,006-1-2-4
D
2016-12-16
OXFDOxford Immunotec Global PlcWrighton-Smith PeterCEOS - Sale+OE$15.07-7,052443,314-2%-$106,241-1-1-10
D
2016-12-05
OXFDOxford Immunotec Global PlcWrighton-Smith PeterCEOS - Sale+OE$15.00-1,140443,3140%-$17,100+5+6+6
DM
2016-12-01
OXFDOxford Immunotec Global PlcWrighton-Smith PeterCEOS - Sale+OE$15.00-61,808443,314-12%-$927,120-100
2016-12-02
VIVOMeridian Bioscience IncElagin Vecheslav AEVP, Research, DevelopmentS - Sale$17.30-7,88353,003-13%-$136,376+2+3+2
DM
2016-11-30
QDELQuidel Corp /de/Bujarski Robert JosephSVP, Bus Dev, GCS - Sale+OE$22.84-60,00041,896-59%-$1,370,221+1+4-4
2016-12-01
APPYBioptix, Inc.Honig Barry C10%P - Purchase$5.04+29,815500,000+6%+$150,257+1-2
2016-11-30
VIVOMeridian Bioscience IncEllingwood Dwight EDirP - Purchase$17.12+1,0207,000+17%+$17,4660+3+2
DM
2016-11-28
IDXXIdexx Laboratories Inc /deAyers Jonathan WCOB, Pres, CEOS - Sale+OE$119.78-27,4241,088,431-2%-$3,284,698-3-20
DM
2016-11-28
QDELQuidel Corp /de/Bryant Douglas CPres, CEOS - Sale+OE$22.89-72,000274,011-21%-$1,647,768-3-3-8
D
2016-11-25
QDELQuidel Corp /de/Tamerius JohnSVP, Strat, Ext AffairsS - Sale+OE$23.50-8,87823,540-27%-$208,633+1-3-8
D
2016-11-23
IDXXIdexx Laboratories Inc /deCraig ThomasDirS - Sale+OE$120.06-8,50024,283-26%-$1,020,519+1-40
2016-11-23
NEOGNeogen CorpHerbert James LCOB, CEOS - Sale$62.95-1,0001,178,2890%-$62,950-1-2+6
D
2016-11-22
NEOGNeogen CorpBradley EdwardVPS - Sale+OE$61.16-21,600122,530-15%-$1,321,0520+1+4
2016-11-21
LNTHLantheus Holdings, Inc.Burgstahler David FDir, 10%S - Sale$9.00-2,500,0004,282,208-37%-$22,500,000-1-8-13
2016-11-21
LNTHLantheus Holdings, Inc.Venkataraman SriramDir, 10%S - Sale$9.00-2,500,0004,282,208-37%-$22,500,000-1-8-13
2016-11-21
LNTHLantheus Holdings, Inc.Avista Capital Partners Gp, LLC10%S - Sale$9.00-2,500,0004,282,208-37%-$22,500,000-1-8-13
2016-11-16
VIVOMeridian Bioscience IncEberly RichardEVP; Pres, Chief Comm OfficerS - Sale$17.00-4,92648,719-9%-$83,757-10+1
D
2016-11-14
NEOGNeogen CorpHerbert James LCOB, CEOS - Sale+OE$61.00-36,000886,212-4%-$2,195,982+1+3+7
2016-11-08
OXFDOxford Immunotec Global PlcEdwardson PeterChief Operations OfficerS - Sale$14.09-4,86948,932-9%-$68,615-10+3
D
2016-11-10
NEOGNeogen CorpYeutter Clayton KDirS - Sale+OE$59.00-4,500500-90%-$265,500-2+1+6
D
2016-11-14
NEOGNeogen CorpQuinlan Steven J.VP, CFOS - Sale+OE$61.28-3,00010,103-23%-$183,842-2+1+6
D
2016-11-09
NEOGNeogen CorpQuinlan Steven J.VP, CFOS - Sale+OE$57.93-3,00010,103-23%-$173,786-1-1+8
D
2016-11-09
IDXXIdexx Laboratories Inc /deAyers Jonathan WCOB, Pres, CEOS - Sale+OE$107.86-40,0001,085,855-4%-$4,314,1870+4+9
2016-11-08
IDXXIdexx Laboratories Inc /deEnd William TDirS - Sale$109.87-5,00048,654-9%-$549,3590+4+9
2016-11-08
OXFDOxford Immunotec Global PlcSandberg Richard ADirS - Sale$14.17-12,00020,174-37%-$170,007-1+1+3
M
2016-09-30
APPYVenaxis, Inc.Honig Barry C10%P - Purchase$2.52+63,42613,400-127%+$159,667-4+4+58
2016-11-07
ICCCImmucell Corp /de/Tomsche David ScottDirP - Purchase$5.19+4,00070,789+6%+$20,760+10+19
2016-11-04
VIVOMeridian Bioscience IncKraeutler John ACOB, CEOP - Purchase$16.13+5,000317,415+2%+$80,666+1+8+12
2016-11-03
VIVOMeridian Bioscience IncBaldini LawrenceEVP, Pres Global OperationsP - Purchase$16.00+4,90095,501+5%+$78,400+1+8+12
2016-10-18
ABIOArca Biopharma, Inc.Keuer Thomas ACOOS - Sale$2.45-48314,900-3%-$1,184-2-3-11
2016-10-05
VNRXVolitionrx LtdKratochvil David MatthewCFOP - Purchase$5.00+10,00010,000New+$50,000+4+8-20
DM
2016-09-30
NEOGNeogen CorpHerbert James LCOB, CEOS - Sale+OE$55.22-12,000886,212-1%-$662,582-1-1-6
D
2016-09-29
NEOGNeogen CorpBradley EdwardVPS - Sale+OE$53.85-5,335122,530-4%-$287,314-1-1-6
D
2016-09-30
NEOGNeogen CorpQuinlan Steven J.VP, CFOS - Sale+OE$55.15-3,00010,103-23%-$165,448-1-1-6
DM
2016-09-28
NEOGNeogen CorpMorrical Terri AVPS - Sale+OE$54.14-9,60039,583-20%-$519,7060-1-7
DM
2016-09-28
QDELQuidel Corp /de/Bryant Douglas CPres, CEOS - Sale+OE$21.76-69,168274,011-20%-$1,504,768-1-1-13
2016-09-20
ABIOArca Biopharma, Inc.Bristow Michael RPres, Chief Exec OfficS - Sale$2.89-1,97288,083-2%-$5,699+20-13-15
2016-09-20
ABIOArca Biopharma, Inc.Keuer Thomas ACOOS - Sale$2.89-71415,383-4%-$2,063+20-13-15
2016-09-20
ABIOArca Biopharma, Inc.Ozeroff Christopher DavidS.VP, GCS - Sale$2.89-1,18518,400-6%-$3,425+20-13-15
2016-09-19
ABIOArca Biopharma, Inc.Selby Brian L.VP, FinanceS - Sale$2.91-4762,550-16%-$1,385+20-13-15
DM
2016-09-09
MYGNMyriad Genetics IncHenderson John TDirS - Sale+OE$20.49-30,00021,800-58%-$614,81600-9-8
2016-09-02
CLDXCelldex Therapeutics, Inc.Keler TiborEVP, CSOP - Purchase$3.32+3,00018,868+19%+$9,960+5+11+27+3
D
2016-08-30
QDELQuidel Corp /de/Bryant Douglas CPres, CEOS - Sale+OE$22.00-2,832274,011-1%-$62,304-10+2+2
D
2016-08-25
IDXXIdexx Laboratories Inc /deHenderson Rebecca MDirS - Sale+OE$110.44-9,9246,754-60%-$1,095,953+2+3+1+30
2016-08-24
NEOGNeogen CorpCalk Richard E JrPres, COOS - Sale$57.47-5,4250-100%-$311,7640+10+12
D
2016-08-23
IMMUImmunomedics IncMarkison Brian ADirS - Sale+OE$2.98-15,00075,446-17%-$44,634-10+18+77
2016-08-24
IMMUImmunomedics IncStark Don CDirS - Sale$2.97-9,90055,848-15%-$29,451-10+18+77
D
2016-08-23
IMMUImmunomedics IncPaetzold Mary EDirS - Sale+OE$2.98-15,00067,474-18%-$44,673-10+18+77
D
2016-08-19
OGXIOncogenex Pharmaceuticals, Inc.Bencich JohnCFOS - Sale+OE$0.57-1,3809,484-13%-$7870-9-17+5
2016-08-22
ICCCImmucell Corp /de/Cunningham DavidDirP - Purchase$7.14+3,0009,404+47%+$21,431+1+1+10-22
2016-08-19
MYGNMyriad Genetics IncCapone Mark ChristopherPres, C.E.O.P - Purchase$21.24+10,000146,026+7%+$212,4000-3-2-12
D
2016-08-15
IDXXIdexx Laboratories Inc /deJohnson Barry CDirS - Sale+OE$111.37-9,9243,560-74%-$1,105,27500-2+27
2016-08-12
MYGNMyriad Genetics IncMcDade Ralph LPres Myriad RBM, Inc.P - Purchase$21.49+1,00056,720+2%+$21,490-1-1-3-21
2016-08-11
VIVOMeridian Bioscience IncMcIlwraith JohnDirP - Purchase$19.57+1,0003,000+50%+$19,5650-2-2-32
2016-08-10
NYMXNymox Pharmaceutical CorpRobinson James GeorgeDirP - Purchase$2.47+5002,952,6000%+$1,235-5+10+24+51
2016-08-10
NEOGNeogen CorpParnell Jack CDirS - Sale$56.87-5,00013,555-27%-$284,347-1-2-1+14
D
2016-08-09
NEOGNeogen CorpHerbert James LCOB, CEOS - Sale+OE$55.60-6,068897,782-1%-$337,361+2-1-1+15
D
2016-08-08
NEOGNeogen CorpHerbert James LCOB, CEOS - Sale+OE$55.24-8,619897,782-1%-$476,07600+6+13
DM
2016-08-05
QDELQuidel Corp /de/Bujarski Robert JosephSVP, Bus Dev, GCS - Sale+OE$22.58-22,05759,896-27%-$498,012-10-2-11
D
2016-08-08
IDXXIdexx Laboratories Inc /deWilliams Michael J PhdEVPS - Sale+OE$108.94-49,56056,537-47%-$5,399,291-1+1+3+30

AAmended filing
DDerivative transaction in filing (usually option exercise)
EError detected in filing
MMultiple transactions in filing; earliest reported transaction date and weighted average transaction price
S - SaleSale of securities on an exchange or to another person
S - Sale+OESale of securities on an exchange or to another person (after option exercise)
F - TaxPayment of exercise price or tax liability using portion of securities received from the company
P - PurchasePurchase of securities on an exchange or from another person
Return to top